200 related articles for article (PubMed ID: 34270544)
1. Rate-of-Kill (RoK) assays to triage large compound sets for Chagas disease drug discovery: Application to GSK Chagas Box.
Cantizani J; Gamallo P; Cotillo I; Alvarez-Velilla R; Martin J
PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009602. PubMed ID: 34270544
[TBL] [Abstract][Full Text] [Related]
2. Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas' disease drug discovery.
MacLean LM; Thomas J; Lewis MD; Cotillo I; Gray DW; De Rycker M
PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006612. PubMed ID: 30001347
[TBL] [Abstract][Full Text] [Related]
3. Chagas disease drug discovery: toward a new era.
Chatelain E
J Biomol Screen; 2015 Jan; 20(1):22-35. PubMed ID: 25245987
[TBL] [Abstract][Full Text] [Related]
4. Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade.
De Rycker M; Thomas J; Riley J; Brough SJ; Miles TJ; Gray DW
PLoS Negl Trop Dis; 2016 Apr; 10(4):e0004584. PubMed ID: 27082760
[TBL] [Abstract][Full Text] [Related]
5. Live-imaging rate-of-kill compound profiling for Chagas disease drug discovery with a new automated high-content assay.
Svensen N; Wyllie S; Gray DW; De Rycker M
PLoS Negl Trop Dis; 2021 Oct; 15(10):e0009870. PubMed ID: 34634052
[TBL] [Abstract][Full Text] [Related]
6. Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi.
Brand S; Ko EJ; Viayna E; Thompson S; Spinks D; Thomas M; Sandberg L; Francisco AF; Jayawardhana S; Smith VC; Jansen C; De Rycker M; Thomas J; MacLean L; Osuna-Cabello M; Riley J; Scullion P; Stojanovski L; Simeons FRC; Epemolu O; Shishikura Y; Crouch SD; Bakshi TS; Nixon CJ; Reid IH; Hill AP; Underwood TZ; Hindley SJ; Robinson SA; Kelly JM; Fiandor JM; Wyatt PG; Marco M; Miles TJ; Read KD; Gilbert IH
J Med Chem; 2017 Sep; 60(17):7284-7299. PubMed ID: 28844141
[TBL] [Abstract][Full Text] [Related]
7. Role of nucleic acid amplification assays in monitoring treatment response in chagas disease: Usefulness in clinical trials.
Sulleiro E; Muñoz-Calderon A; Schijman AG
Acta Trop; 2019 Nov; 199():105120. PubMed ID: 31376368
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic screening approaches for Chagas disease drug discovery.
Chatelain E; Ioset JR
Expert Opin Drug Discov; 2018 Feb; 13(2):141-153. PubMed ID: 29235363
[TBL] [Abstract][Full Text] [Related]
9. Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease.
Riley J; Brand S; Voice M; Caballero I; Calvo D; Read KD
PLoS Negl Trop Dis; 2015 Sep; 9(9):e0004014. PubMed ID: 26394211
[TBL] [Abstract][Full Text] [Related]
10. Current advances in drug discovery for Chagas disease.
Scarim CB; Jornada DH; Chelucci RC; de Almeida L; Dos Santos JL; Chung MC
Eur J Med Chem; 2018 Jul; 155():824-838. PubMed ID: 30033393
[TBL] [Abstract][Full Text] [Related]
11. Challenges in Chagas Disease Drug Discovery: A Review.
Paucar R; Moreno-Viguri E; Pérez-Silanes S
Curr Med Chem; 2016; 23(28):3154-3170. PubMed ID: 27356544
[TBL] [Abstract][Full Text] [Related]
12. Target-based Screening of the Chagas Box: Setting Up Enzymatic Assays to Discover Specific Inhibitors Across Bioactive Compounds.
Salas-Sarduy E; Niemirowicz GT; José Cazzulo J; Alvarez VE
Curr Med Chem; 2019; 26(36):6672-6686. PubMed ID: 31284853
[TBL] [Abstract][Full Text] [Related]
13. Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.
Fonseca-Berzal C; Arán VJ; Escario JA; Gómez-Barrio A
Parasitol Res; 2018 Nov; 117(11):3367-3380. PubMed ID: 30232605
[TBL] [Abstract][Full Text] [Related]
14. Discovery of new potent hits against intracellular Trypanosoma cruzi by QSAR-based virtual screening.
Melo-Filho CC; Braga RC; Muratov EN; Franco CH; Moraes CB; Freitas-Junior LH; Andrade CH
Eur J Med Chem; 2019 Feb; 163():649-659. PubMed ID: 30562700
[TBL] [Abstract][Full Text] [Related]
15. Translational challenges of animal models in Chagas disease drug development: a review.
Chatelain E; Konar N
Drug Des Devel Ther; 2015; 9():4807-23. PubMed ID: 26316715
[TBL] [Abstract][Full Text] [Related]
16. Why hasn't there been more progress in new Chagas disease drug discovery?
Vermelho AB; Rodrigues GC; Supuran CT
Expert Opin Drug Discov; 2020 Feb; 15(2):145-158. PubMed ID: 31670987
[No Abstract] [Full Text] [Related]
17. Drug discovery for chagas disease: A viewpoint.
Kratz JM
Acta Trop; 2019 Oct; 198():105107. PubMed ID: 31351074
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Image-Based Assay for Trypanosoma cruzi Intracellular Forms.
Eufrásio AG; Cordeiro AT
Methods Mol Biol; 2020; 2116():773-780. PubMed ID: 32221954
[TBL] [Abstract][Full Text] [Related]
19. New drugs for neglected infectious diseases: Chagas' disease.
Machado FS; Tanowitz HB; Teixeira MM
Br J Pharmacol; 2010 May; 160(2):258-9. PubMed ID: 20423339
[TBL] [Abstract][Full Text] [Related]
20. Optimization of 1,4-Naphthoquinone Hit Compound: A Computational, Phenotypic, and In Vivo Screening against
Lara LS; Lechuga GC; Moreira CDS; Santos TB; Ferreira VF; da Rocha DR; Pereira MCS
Molecules; 2021 Jan; 26(2):. PubMed ID: 33467422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
